On the heels of yesterday’s story about India reaping the benefits of pharma contract manufacturing, we ran across this statistic: Contract drug production is expected to grow at a rate of 11 percent per year. And it’s expected to hit $299 billion globally by 2014, up from $177 billion…
Let’s say you’re a Big Pharma CEO who needs a new leader for your vaccines unit. Who are you gonna call? Gerberding. Yep, Julie Gerberding, former top dog at the CDC. She has plenty of experience overseeing the selection of recommended immunizations. And she steered the CDC ship through…
Don’t be skeptical of the U.S. government’s recent spate of off-label marketing claims against drugmakers. That’s what AstraZeneca chief (and current chair of the trade group PhRMA) David Brennan ( photo ) told the Wall Street Journal in an interview. Those fines are actually working, Brennan says. Big Pharma…
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Chattem, Inc. (NASDAQ: CHTT) have entered into a definitive agreement under which sanofi-aventis is to acquire 100 percent of the outstanding shares of Chattem in a cash tender offer for $93.50 per share, or approximately $1.9 billion.
Original Source of Sanofi-aventis to Acquire…
And you thought you could stop worrying about re-importation. Just a few days after it was killed off by senators negotiating their healthcare reform deal, it got a new lease on life from the White House. The Obama administration yesterday promised it would press forward with its proposal to…
Has Eli Lilly anointed CFO Derica Rice as heir-apparent to current CEO John Lechleiter ( photo )? Yes, we know Lechleiter has only been in the chief executive’s office for two years now. But as Dow Jones reports, Lechleiter just handed some big responsibilities to Rice, indicating that he’s…
Bristol-Myers Squibb said its stock-swap offer as part of its spinoff of Mead Johnson Nutrition attracted nearly twice as many shares as it can exchange, so holders who tendered at least 100 shares will get 53.8 percent swapped for Mead Johnson stock. Report
Original Source of BMS stockholders flock…
So, who’s more powerful in Washington: Tanning-bed companies or cosmetic-drug makers? The latter, of course–and the proof is in the pudding otherwise known as healthcare reform. The latest Senate legislation scrapped the so-called “Botax” of 5 percent on elective cosmetics procedures in favor of a 10 percent tax on…
Sanofi-Aventis continues its shopping spree with a $1.9 billion deal for the consumer healthcare group Chattem. Aided by the support of Chattem’s board, the French drugmaker will mount a tender offer for all of its stock at $93.50 per share. That’s a 34 percent premium over Friday’s closing price….
Big Pharma made this a big year for Indian drugmakers. As multinational companies sought ways to cut costs and grow revenues, they ramped up their outsourcing programs and partnerships–and that has helped push sales growth past 20 percent for India’s leading drugmakers, such as Ranbaxy Laboratories, Cipla, Dr Reddy’s…